基底前脑胆固醇核的变化与精神分裂症谱中的药物治疗和认知缺陷有关
Julia Schulz1,2, Felix Brandl1,2,3, Michel J Grothe4
1TUM-NIC Neuroimaging Center, Technical University of Munich, School of Medicine, Munich, Germany.
Schizophrenia bulletin
|August 22, 2023
概括
基底前脑胆固醇核 (BFCN) 体积变化在精神分裂症谱中存在差异,与认知缺陷和药物治疗有关. 这些发现突显了精神分裂症中BFCN完整性的改变,影响了认知.
科学领域:
- 神经科学是一个神经科学.
- 精神病学是一个精神病学.
- 神经成像是一种神经成像.
背景情况:
- 胆固醇系统与精神分裂症有关,在患者中观察到基底前脑胆固醇核 (BFCN) 量的减少.
- BFCN变化的作用及其与精神分裂症谱中的认知缺陷的联系,包括有风险的精神状态 (ARMS) 和首次精神病发作 (FEP),仍然不清楚.
研究的目的:
- 调查精神分裂症谱中前后BFCN子集群的结构变化.
- 检查BFCN体积变化与认知,积极和消极症状之间的关联.
- 探索药物的影响,特别是抗胆固醇负担对BFCN结构的影响.
主要方法:
- 对结构性MRI数据进行基于voxel的形态测量 (VBM) 分析.
- 对前后BFCN子集群的评估.
- 包括一个大型的多站点数据集,包括ARMS受试者,FEP患者 (药物和非药物),已确定的精神分裂症 (SCZ) 患者和健康对照.
主要成果:
- 确定的精神分裂症 (SCZ) 显示前部BFCN体积减少,与抗胆固醇药物负担和认知缺陷有关.
- 第一次精神病发作 (FEP) 患者表现出扩大后部BFCN体积,特别是未服用药物的个人,趋向于认知症状相关性.
- 在有风险精神状态 (ARMS) 的人群中没有发现显著的BFCN体积变化.
结论:
- 精神分裂症的BFCN变化是复杂的,非线性,并且在整个疾病谱中存在差异 (前方与后方,扩大与减少).
- 这些结构变化与认知症状有关,并受到药物的影响,包括抗胆效应.
- 这些发现表明,BFCN完整性在精神分裂症中的动态轨迹对于认知功能至关重要,并受到治疗的调节.
相关概念视频
Negative and Cognitive Symptoms of Schizophrenia
93
Negative symptoms of schizophrenia indicate a reduction or absence of typical behaviors and emotional responses found in healthy individuals, while positive symptoms reflect an excess or distortion of normal functioning.
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
93
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
152
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
152
Biological Causes of Schizophrenia
103
Schizophrenia, a severe psychiatric disorder, arises from a complex interplay of biological factors, including genetic predisposition, structural brain abnormalities, neurotransmitter dysregulation, and developmental irregularities. These factors collectively contribute to the onset and progression of the disorder, which typically manifests in late adolescence or early adulthood.
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin...
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin...
103
Alzheimer's Disease: Treatment
213
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
213
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
743
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
743
Alzheimer's Disease: Overview
518
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
518


